Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:30:39.024Z.
Calculation as of: 2026-10-06T13:30:39.024Z.
Quote observation: 2026-10-06T13:30:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d465a3cb364884174ea279f6e96e1b331d3038a7942601b23d7c9becb19c45da
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Avalyn Pharma Inc. Common Stock
Market Cap
$1.20B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.22B
EV/EBITDA Ratio
27.74x
TTM Avg
20.27x
3Y Avg
20.27x
5Y Avg
20.27x
Market Cap
$1.22B
EV/EBITDA Ratio
14.37x
TTM Avg
31.81x
3Y Avg
87.57x
5Y Avg
54.63x
Market Cap
$1.17B
EV/EBITDA Ratio
8.34x
TTM Avg
7.52x
3Y Avg
19.65x
5Y Avg
29.89x
Market Cap
$1.15B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.15B
EV/EBITDA Ratio
N/A
TTM Avg
44.15x
3Y Avg
171.76x
5Y Avg
154.47x
Market Cap
$1.12B
EV/EBITDA Ratio
8.85x
TTM Avg
7.81x
3Y Avg
9.53x
5Y Avg
11.97x
Market Cap
$1.12B
EV/EBITDA Ratio
N/A
TTM Avg
56.92x
3Y Avg
58.14x
5Y Avg
58.14x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $1.20B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.22B | 27.74x | 20.27x | 20.27x | 20.27x |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 14.37x | 31.81x | 87.57x | 54.63x |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.17B | 8.34x | 7.52x | 19.65x | 29.89x |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.26B | N/A | N/A | N/A | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.15B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.15B | N/A | 44.15x | 171.76x | 154.47x |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 8.85x | 7.81x | 9.53x | 11.97x |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | N/A | 56.92x | 58.14x | 58.14x |
| IRadimed Corporation (IRMD)vs › | $1.12B | 35.91x | 40.48x | 32.62x | 34.28x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
